Latham & Watkins advised Novo Holdings A/S (Novo) as the lead investor in the investment. Freeline Therapeutics raised US$120 million in its Series C investment, co-led…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
